Drug intelligence / Profile preview

Flowbiotic

Development stage: Unknown
Lead developer: Zinereo Pharma
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Flowbiotic is a symbiotic dietary supplement developed by Zinereo Pharma, a subsidiary of the Zendal Group, specifically formulated to manage constipation and improve bowel regularity. The product features a combination of three probiotic strains—*Bifidobacterium lactis*, *Bifidobacterium breve*, and *Lactobacillus plantarum*—alongside prebiotics such as resistant maltodextrin and fructooligosaccharides (FOS), and insoluble rye fiber. It is designed to modulate the gut microbiome to reduce intestinal transit time and alleviate evacuation disorders. While it is often marketed within Zinereo's women's health portfolio, its primary therapeutic focus is gastrointestinal health and motility.

Brand names: Flowbiotic

Beyond the preview

Go deeper on Flowbiotic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flowbiotic.

Explore the full profile